Expression of Bcl-2 Family Member Bid in Normal and Malignant Tissues

• Main Authors: Maryla Krajewska, Juan M. Zapata, Ivo Meinhold-Heerlein, Hirad Hedayat, Anne Monks, Herta Bettendorf, Ahmed Shabaik, Lukas Bubendorf, Olli-P. Kallioniemi, Hoguen Kim, Guido Reifenberger, John C. Reed, Stanislaw Krajewski
• Format: Article
• Language: English
• Published: Elsevier 2002-01-01
• Series: Neoplasia: An International Journal for Oncology Research
• Subjects: Bid; Bcl-2; apoptosis; cancer; tissue microarrays
• Online Access: http://www.sciencedirect.com/science/article/pii/S1476558602800069

Bid is the only known Bcl-2 family member that can function as an agonist of proapoptotic Bcl-2-related proteins such as Bax and Bak. Expression of the proapoptotic Bcl-2 family protein Bid was assessed by immunoblotting and immunohistochemical methods in normal murine and human tissues, and in several types of human cancers and tumor cell lines. Bid expression in normal tissues varied widely, with prominent Bid immunostaining occurring in several types of short-lived cells (e.g., germinal center B cells, peripheral blood granulocytes, differentiated keratinocytes) and in apoptosissensitive cells (e.g., adult neurons). Analysis of Bid expression by immunostaining of 100 colon, 95 ovarian, and 254 prostate cancers, as well as 59 brain tumors and 50 lymphomas, revealed evidence of altered Bid regulation in sometypes of cancers. Correlations with clinical outcome data revealed association of higher levels of Bid with longer recurrence-free survival in men with locally advanced (T3 stage) prostate cancer (P=0.04). Immunoblot analysis of Bid protein levels in the NCI's panel of 60 human tumor cell lines revealed a correlation between higher levels of Bid and sensitivity to ribonucleotide reductase (RR)-inhibiting drugs (P<0.0005). Overexpression of Bid in a model tumor cell line by gene transfection resulted in increased sensitivity to apoptosis induction by a RR inhibitor. Taken together, these observations suggest a potential role for Bid in tumor responses to specific chemotherapeutic drugs, and lay a foundation for future investigations of this member of the Bcl-2 family in healthy and diseased tissues.